Puma Biotechnology Inc

Puma Biotechnology Inc Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to advancing cancer treatment through the development and commercialization of innovative therapies. The company's flagship product, NERLYNX, is an oral formulation of neratinib, a tyrosine kinase inhibitor. NERLYNX is approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed or amplified breast cancer, as well as for advanced or metastatic HER2-positive breast cancer in combination with capecitabine. Beyond NERLYNX, Puma Biotechnology is actively developing alisertib, a small molecule inhibitor targeting aurora kinase A, with potential applications in hormone receptor-positive breast cancer, triple-negative breast cancer, small cell lung cancer, and head and neck cancer. The company employs a strategic distribution model, leveraging specialty pharmacy and established distributor networks to ensure broad market access for its products. Puma Biotechnology has forged significant partnerships, including a key license agreement with Pfizer Inc. for the development and commercialization of neratinib and related compounds, alongside various sub-license agreements with international pharmaceutical companies to expand global reach and therapeutic options. This focus on targeted therapies and strategic collaborations positions Puma Biotechnology as a key player in the oncology landscape, aiming to improve outcomes for cancer patients worldwide.